Modality
mRNA
MOA
CAR-T CD19
Target
CGRP
Pathway
Cell Cycle
IgANRSV
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Jun 2027
Phase 2Current
NCT07210864
689 pts·IgAN
2021-01→2027-06·Recruiting
689 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-111.2y awayPh3 Readout· IgAN
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-06-11 · 1.2y away
IgAN
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07210864 | Phase 2/3 | IgAN | Recruiting | 689 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |